



S3 Fig. The changes of immune-marker stained tumor-infiltrating lymphocyte (TIL) expression during neoadjuvant chemotherapy (NAC). CD4⁺ was increased in 14 patients (48%) among 29 evaluable patients. The change of CD4⁺ ranged 0.17 to 2.95. CD8⁺ was increased in 16 patients (55.2%), and the change of CD8⁺ ranged 0.43 to 5.68. FOXP3⁺ was increased in 10 patients (34.5%) with the changes varying 0.08 to 12.44. In case of CD8⁺/FOXP3⁺ ratio, 21 patients (72.4%) showed increase during NAC, and the change ratio ranged 0.21 to 7.92.